Insider Analysis From LEK On Tackling China’s EDL Challenge: Navigating The Changes And Planning For Success
This article was originally published in PharmAsia News
Executive Summary
After a review of the newly listed products on China’s Essential Drug List, LEK believes price declines and market access can be managed and continued growth is possible for originator products added to the EDL.
You may also be interested in...
Insider Analysis From L.E.K Consulting On Expanding In China’s Medtech Market (Part 3 of 3)
Already the fourth largest medtech market in the world, China’s $17 billion medical device industry is expected to more than double in size in the next five years, paving the way for incredible opportunities for growth. Identifying where the opportunities lie, navigating the tendering process and determining the right sales and distribution models are essential for multinational device makers.
Insider Analysis From L.E.K Consulting On Expanding in China’s Medtech Market (Part 2 of 3)
Already the fourth largest medtech market in the world, China’s $17 billion medical device industry is expected to more than double in size in the next five years, paving the way for incredible opportunities for growth. Identifying where the opportunities lie, navigating the tendering process and determining the right sales and distribution models are essential for multinational device makers.
Insider Analysis From L.E.K Consulting On Expanding In China’s Medtech Market (Part 1 of 3)
Already the fourth largest medtech market in the world, China’s $17 billion medical device industry is expected to more than double in size in the next five years, paving the way for incredible opportunities for growth. Identifying where the opportunities lie, navigating the tendering process and determining the right sales and distribution models are essential for device makers wanting to enter China.